.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,358,352

« Back to Dashboard

Claims for Patent: 9,358,352

Title:Dry powder drug delivery system and methods
Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, endocrine disease such as diabetes and/or obesity.
Inventor(s): Smutney; Chad C. (Watertown, CT), Adamo; Benoit (Mount Kisco, NY), Polidoro; John M. (Coventry, CT), Kinsey; P. Spencer (Sandy Hook, CT), Overfield; Dennis (Fairfield, CT), Sahi; Carl (Coventry, CT), Billings; Christine (Danbury, CT), Marino; Mark T. (Danbury, CT)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:13/702,024
Patent Claims: 1. A dry powder inhaler comprising: a) a mouthpiece; b) a housing comprising a cartridge-mounting area and a cartridge, the cartridge comprising a movable container having a dry powder, the container configured to move with respect to the cartridge and the cartridge configured to form a flow path between one or more inlet ports and one or more dispensing ports within the housing; and c) at least one rigid air conduit; wherein the rigid air conduit is configured so that the dry powder inhaler emits greater than about 75% of the dry powder from the container oriented in the container housing as powder particles in a single inhalation, and the powder particles emitted have a volumetric median geometric diameter of less than about 5 microns when the single inhalation through the mouthpiece generates a peak inspiratory pressure of about 2 kPa within two seconds.

2. The dry powder inhaler of claim 1 having a resistance value to airflow ranging from about 0.065 ( kPa)/liter per minute to about 0.200 ( kPa)/liter per minute.

3. The dry powder inhaler of claim 1, wherein the dry powder is a formulation for pulmonary delivery and comprises an amount from about 1 mg to about 30 mg of the dry powder.

4. The dry powder inhaler of claim 1, wherein the dry powder comprises a diketopiperazine or a pharmaceutically acceptable salt thereof.

5. The dry powder inhaler of claim 4, wherein the diketopiperazine is of the formula 2,5-diketo-3,6-bis(N--X-4-aminobutyl)piperazine, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, and glutaryl.

6. The dry powder inhaler of claim 5, wherein the diketopiperazine is ##STR00003##

7. The dry powder inhaler of claim 1, wherein the dry powder comprises a drug or an active agent.

8. The dry powder inhaler of claim 7, wherein the active agent is an endocrine hormone.

9. The dry powder inhaler of claim 1, wherein the dry powder comprises a peptide, a polypeptide, or fragments thereof, a small organic molecule or a nucleic acid molecule.

10. The dry powder inhaler of claim 9, wherein said peptide is insulin, glucagon, glucagon-like peptide-1, parathyroid hormone, oxytocin, oxyntomodulin, peptide YY, an exendin, analogs thereof or fragments thereof.

11. The dry powder inhaler of claim 9, wherein the small organic molecule is a vasodialator, a vasoconstrictor, a neurotransmitter agonist or a neurotransmitter antagonist.

12. The dry powder inhaler of claim 1, wherein the single inhalation generates an area under the curve (AUC) from a pressure versus time curve within one second of at least about 1.0, 1.1 or 1.2 kPa*sec.

13. The dry powder inhaler of claim 1, wherein the container is integrated into the container housing and filled with a dry powder.

14. A method of delivering of a dry powder using a high resistance dry powder inhaler comprising: providing a dry powder inhaler with an airflow resistance value ranging from about 0.065 ( kPa)/liter per minute to about 0.200 ( kPa)/liter per minute, and containing the dose of the dry powder within cartridge comprising a container configured to move with respect to the cartridge to form a flow path for the delivery of the dry powder; applying sufficient force to reach a peak inspiratory pressure of at least 2 kPa within 2 seconds; and generating an area under the curve in the first second (AUC0-1 sec) of a inspiratory pressure versus time curve of at least about 1.0, 1.1 or 1.2 kPa*sec; wherein greater than 75% of the dose of the dry powder is discharged or emitted from the inhaler as powder particles.

15. The method of claim 14, wherein the dry powder is a formulation for pulmonary delivery and comprises an amount from about 1 mg to about 30 mg of the dry powder.

16. The method of claim 15, wherein the dry powder comprises a diketopiperazine or a pharmaceutically acceptable salt thereof.

17. The method of claim 16, wherein the diketopiperazine is of the formula 3,6-bis(N--X-4-aminobutyl)-2,5-diketopiperazine, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, and glutaryl.

18. The method of claim 17, wherein the diketopiperazine is ##STR00004##

19. The method of claim 18, wherein the dry powder formulation comprises fumaryl diketopiperazine microparticles which upon discharge from the dry powder inhaler are measured to have a volumetric median geometric diameter (VMGD) ranging from about 2 .mu.m to 8 .mu.m and a geometric standard deviation of less than 4 .mu.m.

20. The method of claim 14, wherein the dry powder formulation comprises a drug or an active agent selected from the group consisting of a small organic molecule, peptide, polypeptide, a protein, or a nucleic acid molecule.

21. The method of claim 20, wherein the small organic molecule is a vasoactive agent, a neurotransmitter agonist, a neurotransmitter antagonist, or a steroid molecule.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc